Physician profile
Juli D Williams
NPI 1205855699
$2,269.48
in general payments reported to CMS, 2019-2025
24 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $191 · 2021: $196 · 2022: $307 · 2023: $483 · 2024: $198 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $475.74 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $335.97 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $212.52 | 2020-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $147.61 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $129.37 | 2020-2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $121.05 | 2021-2025 | Xarelto, Spravato |
| Amgen INC. | $120.88 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.35 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $99.29 | 2020-2025 | |
| Viiv Healthcare Company | $92.96 | 2025 | |
| Pfizer INC. | $67.66 | 2019-2024 | |
| Astellas Pharma US INC | $62.88 | 2019-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $37.52 | 2023-2025 | Eliquis |
| Glaxosmithkline, LLC. | $36.77 | 2022-2025 | Shingrix |
| Amarin Pharma, INC. | $34.85 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $34.20 | 2019 | |
| Sage Therapeutics, LLC | $32.48 | 2025 | Zurzuvae |
| Dexcom, INC. | $23.61 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.70 | 2019 | |
| Exact Sciences Corporation | $17.64 | 2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $17.07 | 2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $12.82 | 2019 | |
| Corcept Therapeutics | $12.42 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $8.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juli Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.